Clinical trials: Covid19 Vaccination
Covid19
Anti COVID 19 Hyperimmune Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients
Severe ill Patients will be enrolled in the study (n=310) after duly filled consent forms. Recipients will be divided into 2 group, each group contain 155 patients to compare Safety and efficacy of patients in Clinical Trial…
- Trial name
- NCT04891172
- Testing
- Anti COVID 19 Intravenous Immunoglobulin (C-IVIG)
- Where
- Pakistan
- Volunteers
- 310 people
- Sponsor
- Dow University of Health Sciences
Vaccination; Infection, COVID-19
Establishing Immunogenicity and Safety of Needle-free Intradermal Delivery of mRNA COVID-19 Vaccine
COVID-19 vaccines are limited in supply, especially in low- and middle-income countries, leading to substantial morbidity and mortality.
- Trial name
- MILESTONE (NCT05315362)
- Testing
- solid microneedle skin patch, mRNA-1273, standard needle
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
COVID-19, Influenza
Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine
This study is an open-label, single-center, randomized phase IV clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT04801888
- Testing
- Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 0 or day 28., Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 14.
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Covid19, Vaccine Refusal
Use of Construal Level Theory to Inform Messaging to Increase Vaccination Against COVID-19
This study aims to increase uptake of the COVID booster vaccine through messaging informed by Construal Level Theory. Patients in the Mass General Brigham (MGB) health system aged 18 and older who are eligible for the COVID…
- Trial name
- NCT04871776
- Testing
- Messaging informed by construal level theory, Usual Care
- Where
- United States
- Volunteers
- 3,671 people
- Sponsor
- Brigham and Women's Hospital
Coronavirus Disease 2019 (Covid19), Hematopoietic Neoplasms
Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)
The present study is a prospective phase IV study. All participants will receive the anti-Coronavirus Disease 2019 (COVID-19) Vaccine (messenger Ribonucleic acid-based vaccine, BNT162b2 or Comirnaty®, commercialized by…
- Trial name
- NCT04951323
- Testing
- anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Liege
Covid19
Text Message Nudges for COVID-19 Vaccination
The COVID-19 pandemic has caused significant morbidity and mortality across the world. Effective vaccines are now available but underutilized.
- Trial name
- NCT05037201
- Testing
- Text message
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Mitesh Patel
COVID-19
A Study of Booster Immunization With COVID-19 Vaccine,Inactivated Co -Administration With Influenza Vaccine and Pneumococcal Polysaccharide Vaccine
This study is a single center , randomized ,controlled and open-label phase Ⅳclinical trial of the booster immunization with the third dose of inactivated COVID-19 vaccine(CoronaVac)manufactured by Sinovac Research \& Development…
- Trial name
- NCT05499351
- Testing
- Adult group in immunogenicity and safety study of combined immunization, Elderly group in immunogenicity and safety study of combined immunization, Adult group in safety observation study of combined immunization
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Subjects After COVID-19 Vaccination
Liver Injury After COVID-19 Vaccination
The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is still raging across the world and vaccination is expected to lead us out of this pandemic.
- Trial name
- NCT05470894
- Testing
- Approved COVID-19 vaccine
- Where
- 3 sites in Hong Kong, Japan
- Volunteers
- 379 people, healthy volunteers welcome
- Sponsor
- Humanity & Health Medical Group Limited
Allergic Rhinitis, Allergen Immunotherapy
Influences of Allergic Rhinitis and Allergen Immunotherapy on SARS-CoV-2 Vaccination
The study is designed to assess whether allergic rhinitis and allergen immunotherapy affect the humoral response to SARS-CoV-2 Vaccination in adults.
- Conditions
- Allergic Rhinitis, Allergen Immunotherapy, SARS-CoV-2
- Trial name
- NCT05009134
- Testing
- There is no intervention in this study.
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Huazhong University of Science and Technology
Myocarditis
Pathophysiologic Mechanism for MYOcarditis in COVID19 VAccinations ("MYOVAx" Study)
The coronavirus disease 2019 (COVID-19) is an ongoing pandemic which has infected more than 160 million people and caused 3.4 million deaths worldwide till May 2021.
- Trial name
- MYOVAx (NCT05282498)
- Where
- Singapore
- Volunteers
- 50 people
- Sponsor
- National Heart Centre Singapore
Covid19
Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19
Multi-center phase Ib study to evaluate the Modified Vaccinia Virus Ankara (MVA) vaccine against SARS-CoV-2 in seronegative (Part A) and previously SARS-CoV-2-vaccinated individuals (Part B).
- Trial name
- MVA-SARS2-ST (NCT04895449)
- Testing
- MVA-SARS-2-ST
- Where
- 2 sites in Germany
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Immune System Diseases, COVID-19 Vaccine Adverse Reaction
COVID-19 Post-Vaccination Observation
The study started after the second COVID-19 vaccination of the participant with blood spots appearing on the skin with severe arthritis.
- Conditions
- Immune System Diseases, COVID-19 Vaccine Adverse Reaction, Immune System Disorder
- Trial name
- NCT06107348
- Where
- China
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Yang I. Pachankis, PhD
Down Syndrome, SARS-CoV-2 Vaccination
Prospective Monitoring of Antibody Response Following COVID-19 Vaccination in Patients With Down Syndrome.
The risk of severe course of SARS-CoV-2 infection in people with Down Syndrome is substantially increased. The risk of death is 3-10 fold higher than in healthy people.
- Trial name
- PRIDE (NCT05145348)
- Testing
- Immune response to Sars-CoV-2 vaccinations; including COVID-19 vaccin Moderna, Comirnaty (Pfizer) and Vaxzevria (AstraZeneca)
- Where
- Netherlands
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- UMC Utrecht
Hematologic Diseases
Evaluation of the Immune Response to Sars-Covid-19 Vaccines in Haematological Patients: Prospective Single Center Study
The main objective of this study is to investigate the humoral immune response to COVID-19 vaccines in haematological patients, by testing SARS-CoV-2 seroconversion
- Trial name
- Hema-C19-Vax (NCT05074706)
- Testing
- IgG antibodies to Sars-Cov-2, QuantiFERON SARS-CoV-2 test
- Where
- Italy
- Volunteers
- 700 people
- Sponsor
- University of Milano Bicocca
COVID-19
Evaluation of the Impact of the Anti COVID-19 Vaccination Campaign Addressed to the Employees of an Italian Hospital.
Health workers, especially those in patient-facing roles, had a significantly increased risk of COVID-19 infection, having serious outcomes, and risking spreading the virus to patients and staff.
- Trial name
- NCT05774418
- Testing
- BNT162b2 COVID-19 Vaccine
- Where
- Italy
- Volunteers
- 6,649 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
SARS-CoV2 Infection, Immunisation Reaction
Effect of Different SARS-CoV-2 Vaccine Schedules and Vaccination Intervals on Reactogenicity and Humoral Immunogenicity
Investigation of the reactogenicity and immunogenicity of homologous and heterologous vaccine combinations with regard to the formation of SARS-CoV-2 antispike antibodies in health care workers after basic immunization and boost…
- Conditions
- SARS-CoV2 Infection, Immunisation Reaction, Antibody Hypersensitivity, Tolerance
- Trial name
- NCT05076227
- Testing
- IM injection of vaccination (mRNA vaccination), IM injection of vaccination (vector based vaccination)
- Where
- Germany
- Volunteers
- 1,206 people, healthy volunteers welcome
- Sponsor
- Serge Thal
COVID-19
SCALE-UP Utah II: Community-Academic Partnership to Address COVID-19 Conversational Agent Study
The long-term objective of SCALE-UP II is to increase the reach, uptake, and sustainability of COVID-19 testing among underserved populations.
- Trial name
- NCT05533359
- Testing
- Text-Messaging (TM), Conversational Agent (CA), Patient Navigation (PN)
- Where
- United States
- Volunteers
- 2,117 people
- Sponsor
- University of Utah
SARS-CoV-2 Infection, COVID-19
Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People
This was an exploratory Phase I, randomized, observer-blind, active-controlled, dose-escalation trial to evaluate four dose levels (DLs) of BNT162b4 given in combination with BNT162b2 Bivalent (original/Omicron BA.4/BA.5) to…
- Trial name
- NCT05541861
- Testing
- BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg, BNT162b4 5 mcg, BNT162b4 10 mcg
- Where
- 17 sites in United States
- Volunteers
- 383 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19, Vaccine Hesitancy
COVID-19 Vaccine Hesitancy Among Nurses
The purpose of this study is to investigate the correlation of intention to receive COVID-19 vaccine, recommendation behavior, and 5C psychological antecedents among Nurses.
- Conditions
- COVID-19, Vaccine Hesitancy, Vaccination, Nurses
- Trial name
- NCT05212974
- Testing
- Questionnaires
- Where
- Taiwan
- Volunteers
- 4,258 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
COVID-19
Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV).
This is a single-blind, randomised controlled clinical trial to determine the reactogenicity and immunogenicity of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) vaccines (Pfizer-BioNTech or Moderna) as booster dose…
- Trial name
- MIACoV (NCT05228730)
- Testing
- Tozinameran - Standard dose, Tozinameran - fractional dose, Elasomeran - standard dose
- Where
- Australia
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute